ImmunityBio (IBRX) Leases (2019 - 2026)

ImmunityBio (IBRX) has 8 years of Leases data on file, last reported at $33.0 million in Q1 2026.

• Quarterly Leases rose 3.95% year-over-year to $33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.0 million (up 3.95% YoY) and the FY2025 annual result came in at $33.0 million, down 1.06% from the prior year.
• Leases was little changed at $33.0 million in Q1 2026 per IBRX's latest filing, from $33.0 million in the prior quarter.
• Across five years, Leases topped out at $48.1 million in Q2 2022 and bottomed at $31.8 million in Q1 2025.
• The 5-year median for Leases is $35.2 million (2024), against an average of $37.6 million.
• The widest annual swing landed in 2022, when Leases surged 94.6%; it then declined 22.87% in 2023.
• Tracing IBRX's Leases over 5 years: stood at $45.8 million in 2022, then fell by 20.19% to $36.5 million in 2023, then decreased by 8.7% to $33.4 million in 2024, then fell by 1.06% to $33.0 million in 2025, then increased by 0.07% to $33.0 million in 2026.
• Per Business Quant, the three latest IBRX Leases figures stand at $33.0 million (Q1 2026), $33.0 million (Q4 2025), and $33.2 million (Q3 2025).

Peer Comparison